Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.

Travis RC, Appleby PN, Martin RM, Holly JMP, Albanes D, Black A, Bueno-de-Mesquita HBA, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JAMJL, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, Pollak M, Price AJ, Roobol MJ, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Ziegler RG, Key TJ, Allen NE.

Cancer Res. 2016 Apr 15;76(8):2288-2300. doi: 10.1158/0008-5472.CAN-15-1551. Epub 2016 Feb 26.

2.

Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies.

Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P.

Ann Intern Med. 2008 Oct 7;149(7):461-71, W83-8.

3.

Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R.

J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7.

PMID:
11106682
4.

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.

Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, Egevad L, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjønneland A, Grønbaek H, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Berrino F, Mattiello A, Sacerdote C, Palli D, Quirós JR, Ardanaz E, Navarro C, Larrañaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Travezea C, Trichopoulos D, Jenab M, Ferrari P, Riboli E, Kaaks R.

Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1121-7.

5.

Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis.

Harrison S, Lennon R, Holly J, Higgins JPT, Gardner M, Perks C, Gaunt T, Tan V, Borwick C, Emmet P, Jeffreys M, Northstone K, Rinaldi S, Thomas S, Turner SD, Pease A, Vilenchick V, Martin RM, Lewis SJ.

Cancer Causes Control. 2017 Jun;28(6):497-528. doi: 10.1007/s10552-017-0883-1. Epub 2017 Mar 30. Review.

6.

Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.

Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E.

J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106.

PMID:
12122101
7.

Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.

Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D.

Cancer Res. 2003 Jul 15;63(14):3991-4.

8.

Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States).

Li L, Yu H, Schumacher F, Casey G, Witte JS.

Cancer Causes Control. 2003 Oct;14(8):721-6.

PMID:
14674736
9.

Insulin-like growth factors and prostate cancer: a population-based case-control study in China.

Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):421-7.

10.

Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis.

Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM.

Int J Cancer. 2009 May 15;124(10):2416-29. doi: 10.1002/ijc.24202. Review.

11.

Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer.

Rowlands MA, Holly JM, Hamdy F, Phillips J, Goodwin L, Marsden G, Gunnell D, Donovan J, Neal DE, Martin RM.

Cancer Causes Control. 2012 Feb;23(2):347-54. doi: 10.1007/s10552-011-9883-8. Epub 2011 Dec 20.

PMID:
22183619
12.

Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.

Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, Kenfield SA, Stampfer MJ, Giovannucci EL.

Int J Cancer. 2015 May 15;136(10):2418-26. doi: 10.1002/ijc.29295. Epub 2014 Nov 10.

13.

Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.

Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P, Giles GG.

Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1137-41.

14.

Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT.

Rowlands MA, Holly JM, Gunnell D, Donovan J, Lane JA, Hamdy F, Neal DE, Oliver S, Smith GD, Martin RM.

Cancer Res. 2012 Jan 15;72(2):503-15. doi: 10.1158/0008-5472.CAN-11-1601. Epub 2011 Nov 21.

15.

Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.

Wolk A, Mantzoros CS, Andersson SO, Bergström R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D.

J Natl Cancer Inst. 1998 Jun 17;90(12):911-5.

PMID:
9637140
16.

Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan.

Mikami K, Ozasa K, Nakao M, Miki T, Hayashi K, Watanabe Y, Mori M, Sakauchi F, Washio M, Kubo T, Suzuki K, Wakai K, Nakachi K, Tajima K, Ito Y, Inaba Y, Tamakoshi A; JACC Study Group.

Asian Pac J Cancer Prev. 2009 Dec;10 Suppl:57-61.

17.

The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study.

Rowlands MA, Holly JM, Gunnell D, Gilbert R, Donovan J, Lane JA, Marsden G, Collin SM, Hamdy F, Neal DE, Martin RM.

Cancer Causes Control. 2010 Nov;21(11):1829-42. doi: 10.1007/s10552-010-9610-x. Epub 2010 Jul 23.

PMID:
20652394
18.

Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.

Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E.

Cancer Causes Control. 2005 Apr;16(3):255-62.

PMID:
15947877
19.

IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans.

Hernandez W, Grenade C, Santos ER, Bonilla C, Ahaghotu C, Kittles RA.

Carcinogenesis. 2007 Oct;28(10):2154-9. Epub 2007 Aug 27.

PMID:
17724372
20.

Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort.

DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, Le Marchand L.

Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1444-51. Erratum in: Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1825.

Supplemental Content

Support Center